Changes in the Diagnostic Process of Alzheimer Disease: A New Era of Blood-Based Approaches

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.

Related Keywords

United States ,Americans ,Martin Sadowski ,Roche Abeta ,Lynn Bekris ,Eli Lilly ,Michael Alosco ,Amyvid Florbetapir ,Alzheimers Dement ,Amprion Syntap ,National Institute On ,Boston University Chobanian Avedisian School Of Medicine ,Centers For Disease ,Grossman School Of Medicine ,Duke Health ,Medicaid Services ,Drug Administration ,Alzheimer Association ,Centers For Medicare ,Quest Diagnostics ,Approved Biofluid ,National Institute ,Boston University ,Disease Research Center Clinical Core ,Boston University Chobanian ,Avedisian School ,Cleveland Clinic ,Quest Diagnostic ,Disease Control ,Updated October ,Aging Alzheimer ,Cerebrospinal Fluid ,Published June ,Accessed December ,Alzheimers ,Disease ,Sad ,Diagnosis ,Blood Tests ,Treatments ,Recap ,2023 ,Assays ,